

ChemoCentryx, Inc.  
Form 4  
February 14, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
TECHNE CORP /MN/

2. Issuer Name and Ticker or Trading Symbol  
ChemoCentryx, Inc. [CCXI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
614 MCKINLEY PLACE NE  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
02/13/2012

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
 10% Owner  
\_\_\_\_ Other (specify below)

MINNEAPOLIS, MN 55413  
  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| Common Stock                    | 02/13/2012                           |  | C                              | V   | 4,713,566 A <u>1</u>  | 4,713,566  | D                                 |
| Common Stock                    | 02/13/2012                           |  | C                              |   | 1,021,490 A <u>2</u>  | 5,735,056  | D                                 |
| Common Stock                    | 02/13/2012                           |  | P                              |   | 500,000 A \$ 10   | 6,235,056  | D                                 |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

Edgar Filing: ChemoCentryx, Inc. - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title of Underlying Security (Instr. 3) |              |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|--------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date                            | Title        |
| Series A Preferred Stock                   | (1)  | 02/13/2012                           |  | C                              | 5,000,000   | (1)  | (1)  | Common Stock |
| Series B Preferred Stock                   | (1)  | 02/13/2012                           |  | C                              | 1,946,836   | (1)  | (1)  | Common Stock |
| Series C Preferred Stock                   | (1)  | 02/13/2012                           |  | C                              | 1,223,148   | (1)  | (1)  | Common Stock |
| Series D Preferred Stock                   | (1)  | 02/13/2012                           |  | C                              | 1,257,149   | (1)  | (1)  | Common Stock |
| Convertible Promissory Note                | (2)  | 02/13/2012                           |  | C                              | \$ 10,214,900   | (2)  | (2)  | Common Stock |
| Warrant                                    | \$ 20  | 02/13/2012                           |  | A                              | 150,000   | 02/13/2012   | 02/12/2022                                 | Common Stock |

## Reporting Owners

| Reporting Owner Name / Address                                     | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| TECHNE CORP /MN/<br>614 MCKINLEY PLACE NE<br>MINNEAPOLIS, MN 55413 |               | X         |         |       |

## Signatures

Thomas E Oland, CEO 02/14/2012

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: ChemoCentryx, Inc. - Form 4

- The Issuer's Preferred Stock, which had no expiration date, automatically converted to Common Stock at the closing of the Issuer's initial public offering ("IPO") on February 13, 2012 at a conversion ratio of one share of Common Stock for every two shares of Preferred Stock rounded down to the next whole number, for no additional consideration.
- (1) public offering ("IPO") on February 13, 2012 at a conversion ratio of one share of Common Stock for every two shares of Preferred Stock rounded down to the next whole number, for no additional consideration.
  - (2) The principal amount of the Convertible Promissory Note, plus accrued interest, automatically converted upon the closing of the IPO at a conversion price of \$10.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.